Mucinous colorectal adenocarcinoma: influence of mucin expression (Muc1, 2 and 5) on clinico-pathological features and prognosis.
BACKGROUND
Mucinous component is associated with distinct clinical and pathological features and poor survival in colorectal cancer. The purpose of this study was to determine differences in outcomes of patients with mucinous colorectal adenocarcinoma according to the type of mucin expressed.


METHODS
Immunohistochemistry was performed in all tumors of patients who underwent radical surgery between 1998 and 2003 with mucinous colorectal cancer using antibodies against MUC1, 2, and 5. Correlation between immunoexpression and clinical, pathological features and survival was performed.


RESULTS
Of the 418 patients treated in this period, only 35 had a mucinous adenocarcinoma. Of these, 25 were positive for 1 or more mucin expression. MUC2 expression correlated with tumor site and depth of penetration, while MUC5 expression correlated to tumor site. Overall survival was significantly worse for patients with MUC2 expression, and disease-free survival was significantly worse for patients with MUC1 expression.


CONCLUSIONS
Mucin expression may have significant correlation to specific clinical-pathological features and survival of patients with mucinous-type colorectal adenocarcinoma. These differences may reflect distinct molecular mechanisms involved in carcinogenesis of mucinous colorectal adenocarcinoma.
Perez
Rodrigo Oliva
RO
Department of Gastroenterology, University of São Paulo School of Medicine, Rua Manuel da Nóbrega, 1564, São Paulo, SP, 04001-005, Brazil. rodrigo.operez@gmail.com
Bresciani
Bárbara Helou
BH
Bresciani
Cláudio
C
Proscurshim
Igor
I
Kiss
Desiderio
D
Gama-Rodrigues
Joaquim
J
Pereira
Diego Daniel
DD
Rawet
Viviane
V
Cecconnello
Ivan
I
Habr-Gama
Angelita
A
D002288:Adenocarcinoma, Mucinous / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009077:Mucins / Q000378:metabolism*; D009364:Neoplasm Recurrence, Local / Q000378:metabolism; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis
D009077:Mucins